XVA quant Kenyon leaves Lloyds for MUFG

Kenyon jumps ship for similar role in XVA quant modelling


Chris Kenyon has left Lloyds Banking Group to join the Mitsubishi UFJ Financial Group as head of valuation adjustments (XVA) quantitative modelling, according to a spokesperson for MUFG. He will be part of the bank’s front-office solutions team, which develops tools and models to support the trading, sales and risk departments.

Kenyon spent more than five years at Lloyds, most recently as head of XVA quant research. Prior to that, he held two similar roles: in counterparty credit risk at Credit Suisse and in structured credit valuation at Depfa Bank, then a subsidiary of German bank Hypo Real Estate.

Kenyon has contributed considerably to research into XVA pricing and accounting in recent years. Notable papers include MVA by replication and regression, which introduced a framework for pricing margin valuation adjustment (MVA), and papers on accounting of capital valuation adjustment and MVA.

He also co-edited Landmarks in XVA: from counterparty risk to funding costs and capital, a book drawing on all the major papers that have led the evolution in XVA pricing.

Kenyon’s move comes after two similar departures of XVA quants from Lloyds.

Andrew Green, formerly the head of quantitative research at Lloyds and co-author of many of Kenyon’s published works, left the bank in May 2016. He was hired by Scotiabank to develop a new XVA pricing model.

And in July that year, Julian Keenan, then head of the credit valuation adjustment and funding valuation adjustment management team at Lloyds, left the bank to join JP Morgan as the head of its Asia credit portfolio trading team in Singapore.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here